24,363 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 24,363 shares of the medical equipment provider's stock, valued at approximately $1,985,000.

Other large investors have also added to or reduced their stakes in the company. Cetera Investment Advisers grew its position in shares of Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock worth $1,595,000 after purchasing an additional 13,380 shares in the last quarter. Andra AP fonden boosted its stake in Hologic by 224.5% in the 2nd quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider's stock worth $7,083,000 after purchasing an additional 66,000 shares during the period. Swedbank AB grew its holdings in Hologic by 5.2% during the 2nd quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider's stock valued at $121,060,000 after buying an additional 80,575 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Hologic by 17.9% during the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider's stock valued at $312,000 after buying an additional 582 shares during the last quarter. Finally, Quest Partners LLC lifted its holdings in shares of Hologic by 56.1% in the second quarter. Quest Partners LLC now owns 41,492 shares of the medical equipment provider's stock worth $3,081,000 after buying an additional 14,914 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.75% of the company's stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of a number of research reports. Needham & Company LLC reiterated a "buy" rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday. Leerink Partners lowered their price objective on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Raymond James boosted their target price on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. UBS Group increased their price target on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Finally, Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Hologic Stock Performance

Shares of Hologic stock traded down $1.30 during midday trading on Wednesday, hitting $75.53. The company had a trading volume of 3,159,135 shares, compared to its average volume of 1,617,876. The stock has a market cap of $17.14 billion, a price-to-earnings ratio of 22.68, a PEG ratio of 2.37 and a beta of 0.96. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company has a fifty day simple moving average of $79.53 and a 200 day simple moving average of $78.58. Hologic, Inc. has a 12-month low of $68.15 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts' consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company's revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the business posted $0.89 EPS. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.